Early interim 18F-FDG PET in Hodgkin's lymphoma: Evaluation on 304 patients

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 39, Issue 1, 2012, Pages 4-12

  Zinzani, Pier Luigi ^a   Rigacci, Luigi ^b   Stefoni, Vittorio ^a   Broccoli, Alessandro ^a   Puccini, Benedetta ^b   Castagnoli, Antonio ^c   Vaggelli, Luca ^b   Zanoni, Lucia ^a   Argnani, Lisa ^a   Baccarani, Michele ^a   Fanti, Stefano ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

^c MISERICORDIA E DOLCE HOSPITAL   (Italy)

Author keywords

ABVD; Chemotherapy; Early response to treatment; FDG PET scan; Hodgkin's lymphoma

Indexed keywords

BLEOMYCIN; DACARBAZINE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; VINBLASTINE; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SCINTISCANNING; TIME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; DACARBAZINE; DOXORUBICIN; FEMALE; FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RETROSPECTIVE STUDIES; TIME FACTORS; VINBLASTINE; YOUNG ADULT;

EID: 84858785381     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-011-1916-8     Document Type: Article

References (36)

1. Terasawa T, Lau J, Bardet S, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol. 2009;27:1906-14.
2. Kostakoglu L, Coleman M, Leonard JP, et al. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med. 2002;43:1018-27. (Pubitemid 34847924)
3. Torizuka T, Nakamura F, Kanno T, et al. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging. 2004;31:22-8. (Pubitemid 38133537)
4. Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006;107:52-9. (Pubitemid 43053523)
5. Gallamini A, Rigacci L, Merli F, et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica. 2006;91:475-81.
6. Hutchings M, Mikhaeel NG, Fields PA, et al. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol. 2005;16:1160-8.
7. Zinzani PL, Tani M, Fanti S, et al. Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients. Ann Oncol. 2006;17:1296-300.
8. Querellou S, Valette F, Bodet-Milin C, et al. FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease. Ann Hematol. 2006;85:759-67. (Pubitemid 44377874)
9. Schot BW, Zijlstra JM, Sluiter WJ, et al. Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. Blood. 2007;109:486-91. (Pubitemid 46105942)
10. Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-(18F)fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007;25:3746-52. (Pubitemid 47372616)
11. Gobbi PG, Zinzani PL, Broglia C, et al. Comparison of prognostic models in patients with advanced Hodgkin disease: promising results from integration of the best three systems. Cancer. 2001;91:1467-78. (Pubitemid 32319257)
12. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med. 1998;339:1506-14.
13. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol. 1989;7:630-1636. Erratum in: J Clin Oncol. 1990;8:1602.
14. Gobbi PG, Broglia C, Di Giulio G, et al. The clinical value of tumor burden at diagnosis in Hodgkin lymphoma. Cancer. 2004;101:1824-34. (Pubitemid 39314746)
15. Bartlett NL. The present: optimizing therapy - too much or too little? Hematology Am Soc Hematol Educ Program. 2010;2010:108-14.
16. Dodd LE, Korn EL, Freidlin B, et al. Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense? J Clin Oncol. 2008;26:3791-6. Erratum in: J Clin Oncol. 2009;27:2109-2110.
17. Carbone PP, Kaplan HS, Musshoff K, et al. Report of the committee on Hodgkin's disease staging classification. Cancer Res. 1971;31:1860-1.
18. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244-53. Erratum in: J Clin Oncol. 2000; 18:2351. (Pubitemid 29162950)
19. Cheson BD, Pfistner B, Juweid ME, et al. International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579-86. (Pubitemid 350002966)
20. Kaplan ES, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;58:457-81.
21. Spaepen K, Stroobants S, Dupont P, et al. ((18)F)FDG PET monitoring of tumour response to chemotherapy: does ((18)F) FDG uptake correlate with the viable tumour cell fraction? Eur J Nucl Med Mol Imaging. 2003;30:682-8. (Pubitemid 36612950)
22. Barrington SF, Qian W, Somer EJ, et al. Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2009;37:1824-33.
23. Gallamini A, Hutchings M, Avigdor A, et al. Early interim PET scan in Hodgkin lymphoma: where do we stand? Leuk Lymphoma. 2008;49:659-62. (Pubitemid 351517210)
24. Barnes JA, LaCasce AS, Zukotynski K, et al. End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin's lymphoma. Ann Oncol. 2011;22:910-5.
25. Sher DJ, Mauch PM, Van Den Abbeele A, et al. Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin's lymphoma: the importance of involved-field radiotherapy. Ann Oncol. 2009;20(11):1848-53.
26. Straus DJ, Johnson JL, Lacasce S, et al. Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. Blood. 2011;117(20):5314-20.
27. Strobel K, Schaefer NG, Renner C, et al. Cost-effectiveness therapy remission assessment in lymphoma patients using FDG-PET/CT: is an end of treatment exam necessary in all patients? Ann Oncol. 2007;18:658-64.
28. Fanti S, Castellucci P, Stefoni V, et al. Early relapse in a patient with Hodgkin's disease and negative interim FDG-PET. Ann Nucl Med. 2008;22:429-32. (Pubitemid 351938508)
29. Radford JA, Barrington SF, O'Doherty MJ, et al. Interim results of a UK NCRI randomised trial comparing involved field radiotherapy with no further treatment after 3 cycles ABVD and a negative PET scan in clinical stages IA/IIA Hodgkin lymphoma. Haematologica. 2007;92 suppl 5:S32.
30. National Institutes of Health (2011) HD16 for early stage Hodgkin lymphoma. http://www.clinicaltrials.gov/ct2/show/NCT00736320. Accessed 23 Aug 2011
31. National Institutes of Health (2011) Fludeoxyglucose F 18 PET scan-guided therapy or standard therapy in treating patients with previously untreated stage I or stage II Hodgkin's lymphoma. http://www.clinicaltrials.gov/ct2/show/ NCT00433433. Accessed 23 Aug 2011
32. National Institutes of Health (2010) Positron emission tomography (PET)-adapted chemotherapy in advanced Hodgkin lymphoma (HL) (HD0607). http://www.clinicaltrials.gov/ct2/show/NCT00795613. Accessed 23 Aug 2011
33. National Institutes of Health (2010) Fludeoxyglucose F 18-PET/CT imaging in assessing response to chemotherapy in patients with newly diagnosed stage II, stage III, or stage IV Hodgkin lymphoma. http://www.clinicaltrials.gov/ct2/ show/NCT00678327. Accessed 23 Aug 2011
34. National Institutes of Health (2011) High-dose chemotherapy and stem cell transplantation, in patients PET-2 positive, after 2 courses of ABVD and comparison of RT versus no RT in PET-2 negative patients (HD0801). http://www.clinicaltrials.gov/ct2/show/NCT00784537. Accessed 23 Aug 2011
35. National Institutes of Health (2011) HD18 for advanced stages in Hodgkins lymphoma. http://www.clinicaltrials.gov/ct2/show/NCT00515554. Accessed 23 Aug 2011
36. Sánchez-Aguilera A, Montalbán C, de la Cueva P, et al. Spanish Hodgkin Lymphoma Study Group. Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. Blood. 2006;108:662-8.